WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) held its annual general and special meeting on April 25, 2025, with 40.88% shareholder participation representing 59,214,893 common shares. Key approvals included:
- Election of 5 directors with strong majority support (84.5-88.4% approval): Dr. Chris Savile, Dr. Jim Lalonde, Donald Archibald, Raffi Asadorian, and Al Foreman
- Appointment of KPMG LLP as auditor (87.6% approval)
- Sale of Epimeron USA subsidiary (88.4% approval)
- Authorization for potential company name change to '2482118 Alberta ' (82.5% approval)
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) ha tenuto la sua assemblea generale e straordinaria annuale il 25 aprile 2025, con una partecipazione degli azionisti del 40,88%, rappresentante 59.214.893 azioni ordinarie. Le principali approvazioni includevano:
- Elezione di 5 amministratori con un forte sostegno della maggioranza (84,5-88,4% di approvazione): Dr. Chris Savile, Dr. Jim Lalonde, Donald Archibald, Raffi Asadorian e Al Foreman
- Nomina di KPMG LLP come revisore dei conti (87,6% di approvazione)
- Vendita della controllata Epimeron USA (88,4% di approvazione)
- Autorizzazione per un possibile cambio del nome della societ脿 in '2482118 Alberta' (82,5% di approvazione)
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) celebr贸 su junta general anual y extraordinaria el 25 de abril de 2025, con una participaci贸n accionarial del 40,88%, representando 59,214,893 acciones ordinarias. Aprobaciones clave incluyeron:
- Elecci贸n de 5 directores con un fuerte apoyo mayoritario (84,5-88,4% de aprobaci贸n): Dr. Chris Savile, Dr. Jim Lalonde, Donald Archibald, Raffi Asadorian y Al Foreman
- Nombramiento de KPMG LLP como auditor (87,6% de aprobaci贸n)
- Venta de la subsidiaria Epimeron USA (88,4% de aprobaci贸n)
- Autorizaci贸n para un posible cambio de nombre de la compa帽铆a a '2482118 Alberta' (82,5% de aprobaci贸n)
Willow Biosciences (TSX: WLLW, OTCQB: CANSF)電� 2025雲� 4鞗� 25鞚� 鞐半 鞝曣赴 氚� 韸闺硠 欤检＜齑濏殞毳� 臧滌禍頄堨溂氅�, 40.88%鞚� 欤检＜ 彀胳棳鞙 59,214,893 氤错喌欤缄皜 雽�響滊悩鞐堨姷雼堧嫟. 欤检殧 鞀轨澑 靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:
- 臧曤牓頃� 雼れ垬 歆�歆�(84.5-88.4% 鞀轨澑)毳� 氚涭潃 5氇呾潣 鞚挫偓 靹犾稖: Dr. Chris Savile, Dr. Jim Lalonde, Donald Archibald, Raffi Asadorian, Al Foreman
- KPMG LLP毳� 臧愳偓鞚胳溂搿� 鞛勲獏 (87.6% 鞀轨澑)
- 鞛愴殞靷� Epimeron USA 毵り皝 (88.4% 鞀轨澑)
- 須岇偓氇� 氤�瓴� 鞛犾灛鞝� 鞀轨澑 '2482118 Alberta' (82.5% 鞀轨澑)
Willow Biosciences (TSX : WLLW, OTCQB : CANSF) a tenu son assembl茅e g茅n茅rale annuelle et extraordinaire le 25 avril 2025, avec une participation des actionnaires de 40,88 %, repr茅sentant 59 214 893 actions ordinaires. Les principales approbations comprenaient :
- 脡lection de 5 administrateurs avec un fort soutien majoritaire (84,5-88,4 % d鈥檃pprobation) : Dr Chris Savile, Dr Jim Lalonde, Donald Archibald, Raffi Asadorian et Al Foreman
- Nomination de KPMG LLP en tant qu鈥檃uditeur (87,6 % d鈥檃pprobation)
- Vente de la filiale Epimeron USA (88,4 % d鈥檃pprobation)
- Autorisation pour un 茅ventuel changement de nom de la soci茅t茅 en 芦 2482118 Alberta 禄 (82,5 % d鈥檃pprobation)
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) hielt am 25. April 2025 seine j盲hrliche Haupt- und Sonderversammlung ab, mit einer Aktion盲rsbeteiligung von 40,88 %, die 59.214.893 Stammaktien repr盲sentierte. Wichtige Beschl眉sse umfassten:
- Wahl von 5 Direktoren mit starker Mehrheitsunterst眉tzung (84,5-88,4 % Zustimmung): Dr. Chris Savile, Dr. Jim Lalonde, Donald Archibald, Raffi Asadorian und Al Foreman
- Ernennung von KPMG LLP als Wirtschaftspr眉fer (87,6 % Zustimmung)
- Verkauf der Tochtergesellschaft Epimeron USA (88,4 % Zustimmung)
- Genehmigung f眉r eine m枚gliche Namens盲nderung des Unternehmens zu '2482118 Alberta' (82,5 % Zustimmung)
- Strong shareholder support (84.5-88.4%) for all board nominees
- High approval (88.4%) for strategic sale of Epimeron USA subsidiary
- Relatively low shareholder meeting participation at 40.88%
- Potential corporate identity change suggesting significant restructuring
The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:
Votes For | Votes Withheld | |||
Director | # | % | # | % |
Dr. Chris Savile | 46,902,346 | 88.3听% | 6,234,676 | 11.7听% |
Dr. Jim Lalonde | 46,965,380 | 88.4听% | 6,171,642 | 11.6听% |
Donald Archibald听 听 听 | 44,900,287 | 84.5听% | 8,236,735 | 15.5听% |
Raffi Asadorian | 46,963,057 | 88.4听% | 6,173,965 | 11.6听% |
Al Foreman | 46,900,723 | 88.3听% | 6,236,299 | 11.7听% |
In addition, shareholders approved the below matters. The resolutions approving the below matters may be viewed in full in the Company's management information circular dated March听26, 2025 (the "Information Circular").
Votes For | ||
Director | # | % |
Appointment of KPMG LLP as the Company's auditor for the ensuring year | 51,882,364 | 87.6听% |
The proposed sale of the shares of Epimeron | 46,996,397 | 88.4听% |
To authorize the Corporation's board of directors, at its sole discretion, to | 48,853,362 | 82.5听% |
For complete voting results on all matters approved at the Meeting, please see the Company's Report of Voting Results dated April 25, 2025, available on SEDAR+ at .
About Willow Biosciences Inc.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.
For more information, visit or contact:
Travis Doupe
Chief Financial Officer
E: [email protected]听
View original content to download multimedia:
SOURCE Willow Biosciences Inc.
FAQ
What were the key voting results from Willow Biosciences (CANSF) 2025 annual meeting?
What is the significance of Willow Biosciences (CANSF) selling Epimeron USA?
Why is Willow Biosciences (CANSF) considering changing its name to 2482118 Alberta ?
What was the shareholder participation rate at Willow Biosciences' 2025 annual meeting?
